Shots:

• GSK to receive $350M at closing- along with ~$150M as milestones. The transaction is expected to close in H2’21
• The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches
• The agreement includes the global rights to three established brands (Zinnat- Zinacef- and Fortum) in 100+ markets. Additionally- Sandoz plans to expand its integrated manufacturing site in Kundl with the manufacturing of Zinnat

 ­ Ref: Novartis | Image: Novartis